Instead of blindly following new regulations, the medical community must oppose unnecessary rules handed down from the politburo.
Read the rest here:
Category Archives: Medicine
In China, Medicine Costs Fall Under Healthcare Reform
Chinese healthcare reform making prescription drugs more affordable -- report.
See the original post here:
China Botanic's Siberian Ginseng Extract Recognized as Safe Medicine
HARBIN, China, July 3, 2012 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and Traditional Chinese Medicines ("TCM") in China, today announced that the Company's Siberian Ginseng Extract was recognized as Safe Medicine at the 8th session of the Selection Event, hosted by the Health Newspaper in China and supported by the Ministry of Health of China.
In May 2012, at the 8th session of the Selection event, a total of 30 medicines manufactured by 30 Chinese pharmaceutical companies were recognized as Safe Medicine by civilians. Since its debut in 2004, the Selection Event is well known in China's pharmaceutical industry. The selection procedure includes conducting surveys of Chinese consumers and their opinion of products offered by domestic pharmaceutical companies The Selection Event is designed to understand the needs of patients and gain valuable insights from the general population on the quality and remedial effect of different medications.
"We are honored that our Siberian Ginseng Extract product has been recognized as Safe Medicine by our domestic consumers along with 29 other medicines from well-known pharmaceutical companies. We believe this reflects on our commitment to deliver high-quality products which optimally meet our customer's needs," commented Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are encouraged by this recognition as we continue to make efforts to expand the scope and reach of Siberian Ginseng in China and internationally."
For more information on the 8th session of the Selection Event, please visit http://aqyy.jkb.com.cn.
ABOUT CHINA BOTANIC PHARMACEUTICAL INC
China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit http://www.renhuang.com.
Safe Harbor Statement
This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.
Go here to read the rest:
China Botanic's Siberian Ginseng Extract Recognized as Safe Medicine
Ecuador's mix of folk and modern medicine
3 July 2012 Last updated at 21:25 ET By Irene Caselli Riobamba, Ecuador
Please turn on JavaScript. Media requires JavaScript to play.
Patient Jenny Layedra and yachak Mariano Atupana talk about the importance of indigenous treatments
Dressed in a red poncho and traditional hat, Mariano Atupana stands out among the medical staff at the hospital in the Ecuadorean town of Riobamba.
But it is not just his dress that makes him different.
Mr Atupana is a yachak, a medicine man, who uses burning candles and egg yolks to help diagnose ailments.
Yachaks normally see patients in villages in Ecuador's Andes mountains.
But Mr Atupana examines them in a room at Riobamba's Alternative Andean Hospital - a private institution where Western and Andean medicine are practised side by side.
This hospital is one of a number of pioneering projects in Ecuador which are bringing together different types of healthcare.
Patient Jenny Layedra, 44, has come to the hospital because she has been feeling physically weak and tired, and suffering with headaches.
Read more from the original source:
Research and Markets: Personalized Medicine – Scientific and Commercial Aspects
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/sdct5t/personalized_medic) has announced the addition of Jain PharmaBiotech's new report "Personalized Medicine - Scientific and Commercial Aspects" to their offering.
The aim of personalized medicine or individualized treatment is to match the right drug to the right patient and, in some cases, even to design the appropriate treatment for a patient according to his/her genotype. This report describes the latest concepts of development of personalized medicine based on pharmacogenomics, pharmacogenetics, pharmacoproteomics, and metabolomics.
Profiles of 264 companies involved in developing technologies for personalized medicines, along with 486 collaborations are included in the part II of the report. Finally the bibliography contains over 650 selected publications cited in the report.The report is supplemented by 65 tables and 18 figures.
Key Topics Covered:
- Basic Aspects
- Molecular Diagnostics in Personalized Medicine
- Pharmacogenetics
- Pharmacogenomics
- Role of Pharmacoproteomics
More:
Research and Markets: Personalized Medicine - Scientific and Commercial Aspects
Marijuana as Medicine Needs Rules to Drive By
Illustration by Dante Hong Carlos
By Robert Frichtel 2012-07-01T22:30:32Z
Lets start by stating that driving while impaired by drugs or alcohol is a crime and must be punished. All 50 U.S. states have clear laws prohibiting this activity.
But there is one intoxicant that is trickier than the others: marijuana, especially when used for medical purposes.
During the past two years, Colorado and Montana, along with more than a dozen other states, have proposed laws that set a strict threshold for determining when a marijuana user is deemed too impaired to drive. These would consider a concentration of more than 5 nanograms of tetrahydrocannabinol, or THC (the psychoactive component of marijuana) per milliliter of blood, as hands-down proof of intoxication or impairment.
The result would be an automatic guilty verdict, with all that entails: a temporary loss of driving privileges, fines, lawyers fees, possible jail time and greatly increased insurance premiums. By some estimates, a conviction for driving under the influence (DUI) can cost a driver as much as $10,000.
Several states are going further and have either adopted or are considering zero-tolerance laws for THC levels. This means any THC in the blood would result in a conviction.
Heres the problem with these laws: There are questions about how, and at what level, cannabis use impairs driving ability. For a patient in one of the 17 states where marijuana has been legalized for medicinal use, how are you to know when its legal to drive? After consuming marijuana, should you wait 12 hours to drive or one day? When will your THC level be below the 5-nanogram threshold? The answer is complicated.
Although marijuana is readily detectable in toxicology tests of blood, hair, urine or saliva, what isnt clear is just how quickly THC passes through the body. We know, for example, that THC may be detected in the blood of occasional users several hours after ingesting. But in some chronic users there may be traces for days after the last use, long after any performance-impairing effects have subsided.
This is a very clear contrast with alcohol. There is a firm understanding of the rate at which the body metabolizes alcohol and there are well-known guidelines on how much time must pass after drinking before one is fit to drive. Tests can easily be administered in roadside stops. Those who fail simple benchmarks of sobriety -- not to mention breath tests -- are usually convicted or plead guilty.
More here:
Penn Medicine Appoints Brian L. Strom, MD, MPH, as Executive Vice Dean for Institutional Affairs
PHILADELPHIA Brian L. Strom, MD, MPH, has been appointed to the role of Executive Vice Dean for Institutional Affairs, at Penn Medicine. The appointment, made by J. Larry Jameson, MD, PhD, Executive Vice President of the University of Pennsylvania Health System and Dean of the University of Pennsylvania's Perelman School of Medicine, will take effect on March 1, 2012.
In his new role, Strom will assume the responsibilities of coordinating Penn Medicine's efforts in comparative effectiveness research, as well as the Neuroscience of Behavior Initiative, which seeks to strengthen Penn's programs in basic, translational, clinical, and population research in the areas of addiction, depressive disorders, and neurodegenerative disease. In consultation with Dean Jameson, Strom will also provide administrative leadership for the recruitment of department chairs, center and institute directors, and other senior faculty members. Along with other members of Penn
Medicine leadership, he will also assist with implementing recommendations that emerge from the School's current strategic planning process.
Since 2007 Strom has served as vice dean for institutional affairs, with primary responsibilities as Penn Medicine's liaison to the Philadelphia Veteran's Administration Medical Center and Penn's global health programs in Guatemala and Peru. He will continue to serve the Perelman School of Medicine in these areas.
Strom is the founding chair of the Department of Biostatistics and Epidemiology and the founding director of the Center for Clinical Epidemiology and Biostatistics at Penn Medicine. As the George S. Pepper Professor of Public Health and Preventive Medicine, he has served as chair and center director since 1995. Author of more than 550 papers and principal investigator of more than 250 grants, he is an elected member of the Institute of Medicine of the National Academy of Sciences and one of the few clinical epidemiologists elected to the American Society of Clinical Investigation and American Association of Physicians. He is renowned for his work in the field of pharmacoepidemiology, and serves as editor-in-chief for Pharmacoepidemiology and Drug Safety, the official journal of the International Society for Pharmacoepidemiology.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
More:
Penn Medicine Appoints Brian L. Strom, MD, MPH, as Executive Vice Dean for Institutional Affairs
How Socialized Medicine Is Saving My Life
Americans should rejoice in a move towards a European healthcare model. Here's why, according to a 27-year-old MS patient.
View original post here:
Inform Genomics Announces Preliminary Results of OnPART™ Personalized Medicine Product: SNP Network Identifies …
BOSTON--(BUSINESS WIRE)--
Inform Genomics, Inc., a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, today announced preliminary results from its initial study for its lead product, OnPART, which is designed to determine an individuals risk of side-effects associated with chemotherapy regimens based on his or her individual genomic profile. The study utilized advanced Bayesian network technology to identify (single-nucleotide polymorphism) SNP networks associated with common side-effects of chemotherapy regimens. In the plenary session Molecular Predictors in Supportive Care, Dr. Stephen T. Sonis, D.M.D., D.M.Sc. who is a co-founder of Inform Genomics and also a Clinical Professor of Oral Medicine at the Harvard School of Dental Medicine, reported that for patients receiving dose-dense doxorubicin, cyclophosphamide, plus paclitaxel (AC+T) a preliminary SNP network correctly identified patients at risk for chemotherapy-induced diarrhea with an accuracy of 96.7% and an area under the receiver operating characteristic (ROC) curve of 0.994.
We are very encouraged by these early results and they are in line with what we previously demonstrated with a high-degree of precision using our Bayesian network technology to predict oral mucositis with our transplant product, said Ed Rubenstein, President & CEO of Inform Genomics. We are excited to see further data demonstrating OnPARTs ability to predict serious toxicities from chemotherapy regimens based on his or her individual genomic profile which may lead to actions to reduce the burden of potentially curable interventions for patients with cancer.
About OnPART
OnPART, Oncology Preferences And Risk of Toxicity, is Inform Genomics lead platform personalized medicine product for treatment decisions in patients who will receive chemotherapy for colorectal, breast, lung, or ovarian cancer. Based upon response rates and survival, more than one chemotherapy regimen may be considered appropriate care for patients with these common solid tumors, yet the regimens vary widely in their side-effect profiles. OnPART is being developed to assess genomic risk for common and often debilitating therapy-related side-effects, including fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive dysfunction and peripheral neuropathy. The product includes a differentiating factor in personalized medicine, quantifying patient concerns for side-effects, using a copyrighted patient questionnaire (Preference Assessment Inventory). OnPART is expected to provide valuable information for patients and medical oncologists to help clarify critical clinical choices and be commercially available in 2014.
About Cancer Supportive Care
Most patients with cancer receive supportive care as part of their multimodal anti-cancer therapy, regardless of cancer diagnosis, stage of disease, or treatment modality. Common symptoms associated with cancer or its treatments include fatigue, nausea and vomiting, diarrhea, oral mucositis, cognitive dysfunction, and peripheral neuropathy. Some of these conditions are manageable with commercially available medications, while others are the focus of drug development programs. The development of these side-effects may interfere with ongoing anti-cancer treatment, impair patient functioning, negatively impact the patients quality of life, and may increase the risk of mortality. Treatment of these side-effects also results in significant costs for payers and providers.
About Inform Genomics
Inform Genomics, Inc. is a private company focused on developing novel platforms of genomic based personalized medicine products for cancer supportive care and inflammatory diseases, including its lead platform product, OnPART, designed to determine an individuals risk of side-effects associated with chemotherapy regimens based on his or her individual genomic profile. The companys business model leverages existing technology in conjunction with proprietary analytic methods for conducting genome-wide association studies. Product development programs will lead to commercial, single source laboratory tests consisting of single-nucleotide polymorphism (SNP) networks that determine the likelihood of individual patient clinical outcomes to drug therapies. The U.S. market opportunity for these differentiated products exceeds $2 billion annually. Inform Genomics is headquartered in Boston, Massachusetts. For more information, please visit http://www.informgenomics.com.
Continue reading here:
BG Medicine, Inc. Appoints Bill Densel, General Manager, CardioSCORE
WALTHAM, Mass., July 2, 2012 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (BGMD), a company focused on the development and commercialization of novel cardiovascular diagnostics, announced today that Bill Densel has joined the company as General Manager, CardioSCORE. In this role, he will report to President and CEO Eric Bouvier, with overall responsibility for the development and growth of CardioSCORE, BG Medicine's diagnostic blood test designed to improve the identification of individuals at high risk for near-term major cardiovascular events such as heart and stroke. Mr. Densel brings nearly two decades of developing and commercializing breakthrough technologies in medical devices, biotechnology and diagnostics to BG Medicine. He most recently served as Chief Executive Officer of Dune Medical Devices.
"Bill is a welcome and strategically important addition to our management team," said Eric Bouvier, President and Chief Executive Officer of BG Medicine. "We believe that his proven general management experience, coupled with an extensive sales and marketing background focused on cardiology and oncology, will provide us with an ideal skill set to commercialize and build the CardioSCORE franchise, which is a key component of our product portfolio. CardioSCORE is designed to identify high risk patients who would not otherwise be identified using traditional risk scales, particularly in the near-term, and has the potential to enable optimized preventative treatment and save many lives."
Prior to Dune Medical Devices, Mr. Densel held positions of increasing responsibility at Hologic Corporation where he was Vice President of Marketing for the GYN Surgical business and Sr. Director of the Neuroscience Business Unit of Cytyc Corporation. Previously, he held roles in Strategic Planning and Market Development for Boston Scientific. Mr. Densel began his career at Snowden Pencer, a surgical instrumentation company that was acquired by Genzyme Corporation, where he held positions of increasing responsibility in sales, marketing and business development. Following his graduation from Duke University, Mr. Densel received a commission in the U.S. Navy and served for four years as a Special Operations Officer.
About CardioSCORE
CardioSCORE is a diagnostic blood test designed to improve the identification of individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke, over conventional risk factor scoring, in otherwise asymptomatic adults. The test is a proprietary in vitro diagnostic multivariate index assay that measures the levels of several protein biomarkers in blood and integrates the results to yield a single numerical score that is related to an individual's near-term cardiovascular risk. BG Medicine filed a 510(k) Premarket Notification with the U.S. Food and Drug Administration in December 2011 for regulatory clearance of CardioSCORE, following the successful completion of a pivotal clinical validation study.
The American Heart Association estimates that in the United States alone, more than one million people die annually from complications from atherosclerosis and atherothrombosis, and that the total annual cost of treating these conditions exceeds $360 billion.
About BG Medicine, Inc.
BG Medicine, Inc. (BGMD) is a life sciences company focused on the discovery, development, and commercialization of novel cardiovascular diagnostics to address significant unmet medical needs, improve patient outcomes and contain healthcare costs. The Company's first commercialized product, the BGM Galectin-3(TM) test for use in patients with heart failure, is available in the United States and Europe. BG Medicine is also developing CardioSCORE, a blood test designed to identify individuals at high risk for near-term major cardiovascular events, such as heart attack and stroke. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit http://www.bg-medicine.com and http://www.galectin-3.com.
The BG Medicine Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=10352
Safe Harbor Statements under the Private Securities Litigation Reform Act of 1995: Certain statements made in this news release contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, that are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements, which are based on certain assumptions and describe our future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as "believe," "expect," "may," "will," "should," "could," "seek," "intend," "plan," "estimate," "anticipate" or other comparable terms. Forward- looking statements in this news release may address the following subjects, among others: our expectations concerning our belief that CardioSCORE may improve the identification of individuals at high risk for near-term major cardiovascular events over conventional risk factor scoring; our expectations for the market potential of CardioSCORE; our expectation that the FDA will provide regulatory clearance for our CardioSCORE test; and our beliefs regarding expected contributions from our new General Manager. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our recent filings with the Securities and Exchange Commission, including our most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward- looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Continue reading here:
BG Medicine, Inc. Appoints Bill Densel, General Manager, CardioSCORE
Better Health Osteopathic & Integrative Medicine Centre Provides Health Education and Care
Better Health Osteopathic & Integrative Medicine clinic welcomes patients to the multidisciplinary health care and wellness centre.Sydney, Australia (PRWEB) July 01, 2012 Newly opened Better Health Osteopathic & Integrative Medicine clinic welcomes patients to the multidisciplinary health and wellness centre. Specialising in osteopathy, naturopathic medicine, acupuncture and remedial massage ...
Read the original here:
Better Health Osteopathic & Integrative Medicine Centre Provides Health Education and Care
AstraZeneca hungry to refill medicine cabinet
LONDON (Reuters) - Simon Lowth may only be the interim chief executive of AstraZeneca Plc but he is ready to sign off on bold deals. The decision to pair up with Bristol-Myers Squibb Co to buy diabetes specialist Amylin Pharmaceuticals Inc shows the Anglo-Swedish drugmaker is stepping up its deal-making, despite the management hiatus at the top of the company. AstraZeneca is chipping in $3.4 ...
More here:
Regenerative Medicine is Now being Used for Treatment of Avascular Necrosis
Regenerative medicine is now being used for treatment of Avascular Necrosis, according to A. J. Farshchian MD an Orthopedic Regenerative physician at the Center for Regenerative Medicine.(PRWEB) June 30, 2012 Regenerative medicine may help with Avascular Necrosis, according to A. J. Farshchian MD an Orthopedic Regenerative physician at the Center for Regenerative Medicine.Avascular necrosis can ...
Continue reading here:
Regenerative Medicine is Now being Used for Treatment of Avascular Necrosis
Western Michigan University School of Medicine honors Upjohn
W. Mich. med school home named WE Upjohn Campus
KALAMAZOO The new Western Michigan University School of Medicine's future home in downtown Kalamazoo will be named the W.E. Upjohn Campus in honor of the founder of pharmaceutical company Upjohn.
The plans were announced Thursday.
The building once was used for pharmaceutical research as part of the downtown campuses of Upjohn and fellow pharmaceutical companies Pharmacia and Pfizer.
Plans for the building were announced last year. Renovation is expected to be finished by the time the first class of medical students arrives in August 2014.
See more here:
Western Michigan University School of Medicine honors Upjohn
Good Shepherd Welcomes Inaugural Class of Internal Medicine Residents
Good Shepherd Medical Center will welcome its inaugural class of 18 internal medicine residency program participants. These 18 individuals will become the first of a three-year internal medicine residency program based here in Longview. YouTube Video: No YouTube read more
Read more:
Good Shepherd Welcomes Inaugural Class of Internal Medicine Residents
REGION: Alternative medicine going to the dogs
Nine-year-old Dewey rested her head in Sharon Cerkan's lap as the doctor poked a series of needles into her damaged hip.
Cerkan kept Dewey calm as electrical currents charged through the pins and shot into muscle. Some 25 minutes later, after the acupuncture session had ended, Dewey rose without hesitation and ran off to the family van.
Dewey, a Chesapeake Bay retriever/black Labrador mix who lives with Cerkan and her husband, Dan, in Carlsbad, is among the growing number of pets in America being treated with everything from acupuncture to herbal therapy for ailments and diseases that traditional medicine has failed to cure.
"It's becoming more mainstream, and the reason it's becoming more mainstream is it's effective," said Dr. Kathy Boehme, a veterinarian and partner at The Drake Center for Veterinary Care on El Camino Real in Encinitas, where Dewey goes for acupuncture treatments every three weeks.
Boehme calls the strategies used at her clinic integrative medicine. "We're integrating Eastern medicine with Western medicine," she said earlier this month.
Figures are unavailable, but veterinarians who practice alternative medicine say business is booming. A growing number of veterinary schools, including those at Colorado State, Louisiana State and the University of Florida, incorporate integrative medicine into their programs.
"Our membership has grown substantially over the years," said Simon Flynn, the American Academy of Veterinary Acupuncture's executive director. The group now has 825 licensed veterinarians.
"People want every advantage brought to their animal that they can find," he said.
Susan Wynn, president of the American Academy of Veterinary Acupuncture and the former president of the American Holistic Veterinary Medical Association, said more people are accepting alternative care for their pets because more people are open to alternative care for themselves.
She added that people often seek alternatives "because scientifically proven medicine has failed them."
Read the rest here:
Medieval Church's View of Medicine
What the Church did not fully understand was that behind all the practices of medicine including the charms, herbs, and astrology was a real and practical knowledge of the art of medicine. Charms accompanied other medicinal practices and rarely were used alone to heal. Herbs were based on the science of botany though this was not as obvious to many of the time. The science was there but misunderstood by many in power. Science was encouraged when it supported the doctrines and traditions of the Church, but was considered heretical or even satanic when it undermined or contradicted the Church. Despite the periodic oppression by the Church, the science of medicine did advance as more exposure to the East. It was the discovery of the knowledge the Arabs possessed that helped to push Europes medieval practice of medicine. Medicine was not completely absent during the Middle Ages; it was just hampered. Many knew that there was more to medicine than astrology, charms, and incantations. They saw the need to know the causes of sickness and health.
Superstitions can be found in Church writings, but too often the practice of witchcraft in conjunction with medicine caused many to shy away from anything that appeared superstitious. The practice of using the herbs was both encouraged and discouraged by the Church. When the administration of herbs was used with incantations, the Church saw this as non-Christian acts which of course was discouraged to the extent of being examined by the Inquisition. Yet, the superstition of looking to the saints for cures was the Church ordained medicinal practice.
Science, superstition, and spirituality were major components of the medicine practiced during the Middle Ages. The very aspect of each of these parts inevitably brought the Church into the picture. Methods of practicing medicine were feared by the Church when it could hurt it or encouraged by the Church when it could enhance its power and prestige.
Sources:
American Medical Association. Anglo-Saxon Leechcraft. London: Burroughs Wellcome, 1912. Barry, Jonathan and Colin Jones, ed. Medicine and Charity Before the Welfare State. New York: Routledge, 2001. Collins, Minta. Medieval Herbals: The Illustrative Traditions. London: University of Toronto Press, 2000. French, Roger. Medicine Before Science: The Business of Medicine from the Middle Ages to the Enlightenment. New York: Cambridge University Press, 2003. Getz, Faye. Medicine in the English Middle Ages. Princeton: Princeton University Press, 1998. Green, Monica H. trans. The Trotula: A Medieval Compendium of Womens Medicine. Philadelphia: University of Pennsylvania Press, 2001. McVaugh, M.R. Medicine Before the Plague: Practitioners and Their Patients in the Crown of Aragon, 1285-1345. New York: Cambridge University Press, 1993. Mirriam-Webster, http://www.merriam-webster.com/, accessed March 26, 2011. Porterfield, Amanda. Healing in the History of Christianity. New York: Oxford University Press, 2005. Sina, Ibn. On Medicine, Medieval Sourcebook, http://www.fordham.edu/halsall/ source/1020Avicenna-Medicine.html, accessed March 20, 2011. Siraisi, Nancy G. Medieval & Early Renaissance Medicine: an Introduction to Knowledge and Practice. Chicago: Chicago University Press, 1990. Von Bingen, Hildegard. Hildegards Healing Plants. Translated by Bruce W. Hozeski. Boston: Beacon Press, 2001. Walsh, James J. Medieval Medicine. London: A & C Black, 1920.
More here:
Biological Medicine Network to offer Lyme disease seminar
By ANIKA CLARK
June 28, 2012 12:00 AM
NEW BEDFORD The Biological Medicine Network has announced an upcoming two-day seminar on Lyme disease treatment.
The seminar is scheduled for Sept. 20-21 at the Waypoint Event Center at the Fairfield Inn & Suites New Bedford.
The Biological Medicine Network is a program of the Marion Institute, according to network director Barbara Christian. She said the network's activities include organizing seminars and educational trainings with network co-founder Dr. Thomas Rau of Switzerland's Paracelsus Klinik and with other practitioners of biological medicine.
The network's website describes biological medicine as providing a holistic approach to healing and examining root causes of ailments.
The field incorporates practices ranging from natural European remedies to Chinese herbalism, according to the Biological Medicine Network.
September's seminar offers an approach to treating Lyme disease rooted in biological medicine and featuring four practitioners one of whom suffers from Lyme disease himself, Christian said.
"The overall importance is the different way of looking at stuff how everything ties together and supporting the person as a complete unit, while at the same time customizing," said Robert Milisen, one of the presenting practitioners, who earned a doctorate of naturopathic medicine at the Southwest College of Naturopathic Medicine and Health Sciences in Tempe, Ariz.
Milisen's topics include therapy designed to open biofilms, which he said are bubble-like walls built by microbes and impenetrable by antibodies. He will also address preparing patients for treatment.
See more here:
Penn Medicine Emergency Physician Appointed to Federal Council For Emergency Medical Services on Nation's Roadways
PHILADELPHIA Roger A. Band, MD, an assistant professor of Emergency Medicine at the Perelman School of Medicine at the University of Pennsylvania, has been appointed to serve on the National Emergency Medical Services Advisory Council (NEMSAC), which advises the National Highway Traffic Safety Administration (NHTSA) on all EMS matters and related issues on the nation's roadways.
U.S. Transportation Secretary Ray LaHood appointed Band to the post alongside other leaders in the emergency medical services (EMS). "The leadership and professional expertise of the new Council members will help NHTSA ensure that the nation's emergency response services have the most up-to-date information so they can focus on saving lives," said Secretary LaHood. Administered by NHTSA, the NEMSAC provides expert advice and recommendations to the safety agency and its federal partners on key issues including recruitment and retention of EMS personnel, quality assurance, data collection and EMS education over the course of a two-year term.
Band has led several research projects on out-of-hospital cardiac arrest and is the author of numerous papers on prehospital emergency care, including the delivery of resuscitative care for cardiac arrest patients and interventions for other critically ill patients, such as those with penetrating trauma injuries and sepsis. He also serves as a reviewer for several of trauma- and emergency medicine-related journals, and was an EMT and paramedic for over ten years.
He graduated with a B.S. in Microbiology and a minor in Chemistry from the University of Florida and earned his medical degree Jefferson Medical College. He came to the University of Pennsylvania in 2001 to pursue his Emergency Medicine residency training and joined the department's faculty in 2005. In addition to his clinical and administrative responsibilities in the Emergency Medicine department, Band serves as the Medical Director for developing world travel for the WJ Clinton Foundation, personal physician to former President Clinton, and as medical advisor for the University of Pennsylvania Police Department's Emergency Response Team.
To read the full press release about the new appointments, visit the National Highway Traffic Safety Administration's web site.
###
Penn Medicine is one of the world's leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation's first medical school) and the University of Pennsylvania Health System, which together form a $4.3 billion enterprise.
The Perelman School of Medicine is currently ranked #2 in U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $479.3 million awarded in the 2011 fiscal year.
The University of Pennsylvania Health System's patient care facilities include: The Hospital of the University of Pennsylvania -- recognized as one of the nation's top 10 hospitals by U.S. News & World Report; Penn Presbyterian Medical Center; and Pennsylvania Hospital the nation's first hospital, founded in 1751. Penn Medicine also includes additional patient care facilities and services throughout the Philadelphia region.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2011, Penn Medicine provided $854 million to benefit our community.
Here is the original post:
Research and Markets: Skeletal Biology and Medicine II: Bone and cartilage homeostasis and bone disease
DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/xlqrsk/skeletal_biology_a) has announced the addition of John Wiley and Sons Ltd's new book "Skeletal Biology and Medicine II: Bone and cartilage homeostasis and bone disease" to their offering.
The volume features current basic, clinical, and translational research on aspects of skeletal morphogenesis and remodeling in health and disease. Papers survey vital new insights into the mechanisms of bone development and restructuring, including cellular and mechanical triggers, receptors and signaling pathways. Also covered are the effects of other physiological systems and disease states, such as immune system inflammation, diabetes, infection, and cancer on musculoskeletal health. Recent findings are shaping therapeutic directions that focus on both anti-resorptive and anabolic therapies.
Basic scientists, clinical investigators, and clinicians with interests spanning endocrinology, physiology, cell biology, pathology, genetics, molecular biology, rheumatology, oncology, and other areas that relate to bone development and homeostasis will find this a valuable resource for the most recent developments in skeletal biology and medicine.
This volume presents manuscripts stemming from the 4th New York Skeletal Biology and Medicine Conference, held at Mount Sinai School of Medicine in New York City on April 27-30, 2011. The papers included in this volume include two of the topic areas presented at the conference; the other topic areas are included in Skeletal Biology and Medicine I.
For more information visit http://www.researchandmarkets.com/research/xlqrsk/skeletal_biology_a
Source: John Wiley and Sons Ltd
Link: